Clinical Trial Update: Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease [Phase 3]

View source ↗

Summary

ISU Abxis Co., Ltd. is conducting a Phase 3 trial to evaluate the safety and efficacy of Fabagal (agalsidase beta) for Fabry disease, with patient recruitment o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Fabagal (agalsidase beta)

Snippet

Sponsor: ISU Abxis Co., Ltd. | Conditions: Fabry Disease | Phase 3 | Status: RECRUITING